Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
At the new centre, customers get a real-time experience of the process of genetic testing and actionable plans in preventive healthcare under the expertise of certified genetic counsellors
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
High level of vaccine efficacy maintained over a 6-month period of surveillance
Subscribe To Our Newsletter & Stay Updated
